Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott (ABT) aims to provide a new treatment option for patients with CLI BTK, thus eliminating the need for any additional treatment.

Abbott Begins BTK Clinical Trial to Evaluate DRS Therapy

AstraZeneca

Pfizer

Want to get in on a coronavirus healthcare investment? It's not too late.

3 Top Coronavirus Stocks to Buy in September

Teladoc

Viemed Healthcare

It's time for investors to adapt to a new normal.

4 Strategies for Investing During the Coronavirus Pandemic

Tandem Diabetes Care

Vertex Pharmaceuticals

These three stocks are among the few winners to emerge from the coronavirus stock market.

Next Coronavirus Market Crash: Where to Invest $1,000

General Electric

Medtronic

Myriad Genetics

Zimmer Biomet Hlds

Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.

3 Coronavirus-Led Threats to MedTech That May Linger

Abbott's (ABT) FreeStyle Libre 2 iCGM is now available to Medicare-eligible diabetic patients via CMS' reimbursement expansion.

Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects

The medical device maker just secured an FDA approval that could be a game-changer in the fight against COVID-19.

Why Abbott Stock Is Up

SPDR Gold Trust

Invesco QQQ

SPDR S&P 500 ETF Trust

Coronavirus Impact on Consumer Behavior

Abbott Laboratories (NYSE: ABT) shares rallied Thursday after the company's rapid COVID-19 test received emergency use authorization from the FDA.

Abbott Analyst: Expert View On Rapid Coronavirus Antigen Test 'Clearly Bullish'

GlaxoSmithKline

Vir Biotechnology

Market Waits for Major Economic Data This Week.

Market Waits for Major Economic Data This Week

Biogen

Johnson & Johnson

Here Are Warren Buffett's Favorite Coronavirus Stocks

Becton, Dickinson and Co.

QuidelOrtho Corp

With more competition for rapid antigen tests on the way, is Quidel or Becton, Dickinson a better buy?

Competition in the Coronavirus Rapid Test Market: What Does it Mean for Quidel and Becton, Dickinson?

"We are running our clinical trial and we'll eventually have data to be able to support that," Abbott Laboratories CEO Robert Ford told CNBC.

Abbott is testing its rapid coronavirus test on asymptomatic people in hopes of expanding FDA authorization

A Relative Strength Rating upgrade for Abbott Laboratories shows improving technical performance.
The post Abbott Laboratories Meets 80-Plus Relative Strength Rating Benchmark appeared first on Investor's Business Daily.

Abbott Laboratories Meets 80-Plus Relative Strength Rating Benchmark

Most rapid antigen tests in the United States require an additional system, which is making the procedures more costly and complex.

Price War in Coronavirus Test Space to Intensify Thanks to Abbott

Abbott (ABT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Abbott (ABT) Looks Good: Stock Adds 7.9% in Session

The healthcare giant announced a major breakthrough in the coronavirus testing market -- and a blockbuster deal with the U.S. government.

Why Abbott Laboratories Stock Surged Today

The reason for this good news comes from two specific areas, both of which hit the news cycle ahead of today's open.

"Great Reopening" Gets 2 Big Boosts: Fed & Abbott

Ulta Beauty

Walmart

Walmart, Abbott Labs, Ulta Beauty and Quidel were our top stock trades for Friday. So, here's what the charts are trying to tell us now.

4 Top Stock Trades for Friday: WMT, ULTA, ABT, QDEL

Abott’s pocket-sized, $5, 15-minute COVID-19 test was just granted emergency use authorization.
Abbott Laboratories has just been granted emergency use authorization by the Food and Drug Administration for its pocket-sized, $5, 15-minute COVID-19 antigen test.

Abbott’s rapid COVID-19 test: Here’s how it’s different from the rest

The Trump administration has struck a $750 million deal with Abbott Laboratories ABT, +8.26% to buy 150 million of the company's new rapid-response COVID-19 antigen tests.

Trump administration makes $750 million deal to buy 150 million of Abbott's new coronavirus tests

A recently authorized point-of-care COVID-19 test could be the most popular one yet.

Abbott to Receive Order for 150 Million Rapid COVID-19 Tests

Microsoft

A fast and cheap test could hasten the economic recovery, and Microsoft is now working with Walmart to acquire the popular social media app.

Dow Jones Jumps on Rapid COVID-19 Test; Microsoft and Walmart Team Up for TikTok Bid

President Donald Trump plans to announce Thursday the purchase of 150 million rapid Covid-19 tests as part of a $750 million agreement with Abbott Laboratories, a White House official confirmed to NBC News.

Trump to announce $750 million deal with Abbott for at least 150 million rapid coronavirus tests

Hope for an end to coronavirus worries is continuing the bull market run.

News for Abbott Labs Stock (ABT)